Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
Drug Costs
321 - 340 of 702 Results
-
-
As Medicare Enrollment Nears, Popular Price Comparison Tool Is Missing
For more than a decade, customers used the online plan finder to compare dozens of policies. Yet after a redesign of the website, the search results no longer list which plan offers a customer the best value. Federal officials say it will be fixed before enrollment begins next week.
By Susan Jaffe -
KHN’s ‘What The Health?’: Impeachment And The Health Agenda
Washington is abuzz with impeachment talk, but what impact would such a move have on congressional action on prescription drug prices and surprise bills? Also, a study out this week shows that health insurance costs for both employers and workers continue to rise. This week, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
-
As Off-Label Use Spreads, Supplies Of Niche Drugs And Patients’ Patience Grow Short
The reasons behind one particular shortage of a therapy known as IVIG are complicated, stemming from increased demand and the medication’s long production window.
-
Hill Hodgepodge: Pelosi Draws From Democrats, GOP And Trump For Drug Plan
The House speaker announced her plan for lowering drug prices, which includes negotiations between drugmakers and federal health officials.
-
KHN’s ‘What The Health?’: Tennessee Seeks Medicaid Changes
Tennessee wants to convert its Medicaid program to a block grant. But is its plan legal? Meanwhile, Congress continues to struggle with legislation to rein in prescription drug prices and surprise medical bills. This week, Anna Edney of Bloomberg News, Jennifer Haberkorn of the Los Angeles Times and Kimberly Leonard of the Washington Examiner join KHN’s Julie Rovner to discuss these issues and more. Rovner also interviews Dr. Marty Makary, author of the new book “The Price We Pay” about why health care costs so much.
-
Purveyors Of Black-Market Pharmaceuticals Target Immigrants
Illegal medications, sold in immigrant communities around the United States, can cause serious harm to consumers, authorities say. Law enforcement officers are cracking down, but some think more must be done.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
KHN’s ‘What The Health?’: Despite Booming Economy, Uninsured Rate Ticks Up
Nearly 2 million more Americans were uninsured in 2018 than in the previous year, according to the Census Bureau’s annual report. Plus, the Trump administration announced plans to ban flavored vape liquids, and Congress is back and working to address high prescription drug prices and “surprise” medical bills. This week, Joanne Kenen of Politico, Tami Luhby of CNN and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
-
Legislation To End Surprise Medical Bills Has High Public Support — In Both Parties
Almost 80% of Americans support efforts in Congress to protect patients from bills that come from doctors or hospitals that were outside their insurance network.
-
States Pass Record Number Of Laws To Reel In Drug Prices
So far this year, 33 states have enacted more than 50 measures to address drug prices, affordability and access. Congress is eyeing the efforts to see what works.
-
Listen: India Gives Opioid Makers A Huge And Growing New Market
KHN's Sarah Varney discussed opioid painkillers in India with NPR's Rachel Martin on "Morning Edition" Thursday.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
Shopping At The Apotheke: Compare German Pharmacies With Your Corner Drugstore
Germany’s pharmacies provide insights into the country’s low drug prices and strict regulations. But they’re still businesses.
-
In India’s Slums, ‘Painkillers Are Part Of The Daily Routine’
As the Indian government reluctantly loosens its prescription opioid laws after decades of lobbying by palliative care advocates desperate to ease their patients’ pain, the nation’s sprawling, cash-fed health care system is ripe for misuse.
By Sarah Varney -
Beset By Lawsuits And Criticism In U.S., Opioid Makers Eye New Market In India
What began in India as a populist movement to bring inexpensive morphine to the diseased and dying poor has paved the way for a booming pain management industry. Now, new customers are being funneled to U.S. drugmakers bedeviled by a government crackdown back home.
By Sarah Varney -
Pharma Cash Rolls Into Congress To Defend An Embattled Industry
Congress has a variety of reforms in mind that could roil the drugmaking business and potentially slash prices.
-
Addiction Clinics Market Pricey, Unproven Treatments To Desperate Patients
An amino acid infusion called NAD is not approved by the FDA to treat addiction. Yet patients with addiction can be desperate enough to try it, at prices as high as $15,000.
-
Readers And Tweeters Take Dialysis Providers To Task: Nowhere But In The USA
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
KHN’s ‘What The Health?’: All About Medicare
Before “Medicare for All,” there was just Medicare, the federal program that provides insurance to 60 million Americans. This week, KHN’s Julie Rovner talks to Tricia Neuman of the Kaiser Family Foundation about how Medicare works and whom it serves. Then, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Kimberly Leonard of the Washington Examiner join Rovner to talk about some current Medicare issues being debated in Washington, D.C.